Reference | ||
---|---|---|
Reference Type | Literature | IEDB_Reference:1009746 |
Title | Identification of T- and B-cell epitopes of the S2 and S3 subunits of pertussis toxin by use of synthetic peptides. | |
Authors | P Chong; G Zobrist; C Sia; S Loosmore; M Klein | |
Affiliations | Connaught Centre for Biotechnology Research, Connaught Laboratories Ltd., Willowdale, Ontario, Canada. | |
Journal | Infect Immun | |
Year | 1992 | |
Abstract | To design an optimized synthetic vaccine against whooping cough, we have studied the biological and immunological properties of three peptides of the S2 subunit and nine overlapping synthetic peptides covering the entire sequence of the S3 subunit of pertussis toxin (PT). Synthetic peptides corresponding to sequences 18 to 41, 78 to 108, 134 to 154, and 149 to 176 of S3 were found to be consistently capable of stimulating the proliferation of PT-specific T-cell lines primed with pertussis toxoid in both BALB/c and A/J strains of mice. All synthetic peptides were recognized by rabbit antisera raised against PT or pertussis toxoid. Both S2 and S3 peptide-keyhole limpet hemocyanin (KLH) conjugates in the presence of complete Freund's adjuvant induced peptide-specific antibody responses in rabbits, and the antisera raised against S2(1-23), S3(18-41), S3(37-64), and S3(149-176) peptide-KLH conjugates cross-reacted with both subunits in the immunoblots. All antisera except those against S2(123-154) and S3(103-127) reacted with native PT in an enzyme-linked immunosorbent assay (ELISA) with PT directly coated onto microtiter wells. In contrast, antisera raised against S2(123-154), S3(1-23), S3(18-41), S3(37-64), S3(60-87), and S3(103-127) peptide-KLH conjugates recognized native PT in a fetuin-PT capture ELISA. S2(78-98), S3(1-23), and S3(149-176) peptide-KLH conjugates elicited good PT-neutralizing antibody responses as judged by the antitoxin CHO cell assay. Identification of these B-cell neutralization epitopes and T-cell immunodominant determinants represents a first step towards the rational design of a synthetic vaccine against whooping cough. | |
Curation Last Updated | 2023-08-18 20:32:51 |
Epitope | ||
---|---|---|
Epitope ID | 1508 | IEDB_epitope:1508 |
Chemical Type | Linear peptide | |
Linear Sequence | AGFIYRETFCITTIYKTGQPAADHYYSKVTA | |
Source Molecule Name | Pertussis toxin subunit 3 precursor | |
Source Organism | Bordetella pertussis | |
Starting Position | 106 | |
Ending Position | 136 |
Epitope Reference Details | ||
---|---|---|
Epitope Structure Defines | Epitope containing region/antigenic site | |
Epitope Name | PT S3(78-108) | |
Location of Data in Reference | Table 1 |
Immunization | ||
---|---|---|
Host Organism | Mus musculus BALB/c |
1st In Vivo Process | ||
---|---|---|
In Vivo Process Type | Administration in vivo |
Administration Details | ||
---|---|---|
Dose Schedule | 1 doses of 5ug. |
1st Immunogen | ||
---|---|---|
Epitope Relation | Source Antigen | |
Chemical Type | Protein | |
Molecule Name | Pertussis toxin subunit 3 precursor | |
Organism | Bordetella pertussis |
Immunization Comments | ||
---|---|---|
Immunization Comments | Mice were primed with 5ug of pertussis toxoid in A1P04. |
T Cell Assay | ||
---|---|---|
Qualitative Measurement | Positive-High | |
Method/Technique | 3H-thymidine | |
Measurement of | proliferation |
Effector Cells | ||
---|---|---|
Effector Cell Tissue Type | Spleen | |
Effector Cell Type | Splenocyte | |
Effector Cell Culture Conditions | Direct Ex Vivo |
Antigen Presenting Cells | ||
---|---|---|
Cell Tissue Type | Spleen | |
Cell Type | Splenocyte | |
Cell Culture Conditions | Direct Ex Vivo |
MHC Allele | ||
---|---|---|
MHC Allele Name | H2-d class II | |
MHC Evidence Code | T cell assay -Biological process measured |
Antigen | ||
---|---|---|
Epitope Relation | Epitope | |
Chemical Type | Linear peptide | |
Linear Sequence | AGFIYRETFCITTIYKTGQPAADHYYSKVTA | |
Source Molecule Name | Pertussis toxin subunit 3 precursor | |
Source Organism | Bordetella pertussis | |
Starting Position | 106 | |
Ending Position | 136 |
Assay Reference Details | ||
---|---|---|
Location of Assay Data in Reference | Figure 3B |